Abbott Laboratories
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABT research report →
About the company
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine.
- CEO
- Robert Ford
- IPO
- 1980
- Employees
- 114,000
- HQ
- Abbott Park, IL, US
Price Chart
- Market Cap
- $153.59B
- P/E
- 24.55
- P/S
- 3.40
- P/B
- 2.96
- EV/EBITDA
- 17.26
- Div Yield
- 2.77%
- Gross Margin
- 56.38%
- Op Margin
- 18.17%
- Net Margin
- 13.91%
- ROE
- 12.20%
- ROIC
- 6.56%
- Revenue
- $44.33B · 5.67%
- Net Income
- $6.52B · -51.32%
- EPS
- $3.74 · -51.24%
- Op Income
- $8.05B
- FCF YoY
- 16.44%
- 52W High
- $139.06
- 52W Low
- $81.97
- 50D MA
- $91.22
- 200D MA
- $114.49
- Beta
- 0.62
- Avg Volume
- 13.06M
Get TickerSpark's AI analysis on ABT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 28, 26 | Moreland Mary K | other | 5,314 |
| Apr 24, 26 | Conroy Kevin T | other | 2,286 |
| Apr 24, 26 | Conroy Kevin T | other | 0 |
| Apr 24, 26 | Stratton John G | other | 2,286 |
| Apr 27, 26 | STARKS DANIEL J | buy | 10,000 |
| Apr 24, 26 | STARKS DANIEL J | other | 2,286 |
| Apr 24, 26 | STARKS DANIEL J | other | 7,105 |
| Apr 24, 26 | Roman Michael F | other | 2,286 |
| Apr 24, 26 | O'Grady Michael | other | 2,286 |
| Apr 24, 26 | O'Grady Michael | other | 5,929 |
Our ABT coverage
Recent articles, reports, and earnings notes.
Abbott Laboratories (ABT): Buy on Pullbacks, Hold Near Fair Value
Abbott Laboratories is a diversified healthcare compounder with improving growth across medical devices, diagnostics, nutrition, and emerging-market pharmaceuticals. The stock looks high quality but fairly valued, making it more attractive on pullbacks than at current levels.
Inside Our Top Dividend Kings Stock Picks for 2026
These seven Dividend Kings combine long payout streaks with durable businesses, but McDonald’s, Procter & Gamble, and Colgate stand out most on overall quality.
The Best Healthcare Stocks Right Now (Updated June 2026)
These seven healthcare stocks combine recurring demand, identifiable franchises, and varying mixes of scale, profitability, and growth heading into June 2026.
Want a deeper read on ABT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.